Trial · NCT03336619
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time From First Dose to Symptom Response | Nitazoxanide | 155.1 | Inter-Quartile Range 103.7 to 266.3 | hours | |
| Time From First Dose to Symptom Response | Placebo | 153.9 | Inter-Quartile Range 100.2 to 270.7 | hours | |
| Time From First Dose to Ability to Perform All Normal Activities | Nitazoxanide | 201.8 | Inter-Quartile Range 126.6 to 362.7 | hours | |
| Time From First Dose to Ability to Perform All Normal Activities | Placebo | 200.8 | Inter-Quartile Range 127.5 to 347.2 | hours | |
| Number of Subjects Experiencing One or More Complications of Influenza | Nitazoxanide | 50 | Participants | ||
| Number of Subjects Experiencing One or More Complications of Influenza | Placebo | 45 | Participants | ||
| Time to Symptom Response Excluding the FLU-PRO Gastrointestinal and Eye Domains | Nitazoxanide | 152.2 | Inter-Quartile Range 100.8 to 248.9 | hours | |
| Time to Symptom Response Excluding the FLU-PRO Gastrointestinal and Eye Domains | Placebo | 151.7 | Inter-Quartile Range 97.8 to 268.7 | hours | |
| Time to Return to Usual Health | Nitazoxanide | 176.6 | Inter-Quartile Range 120.0 to 315.0 | hours | |
| Time to Return to Usual Health | Placebo | 202.1 | Inter-Quartile Range 126.6 to 322.1 | hours | |
| Proportion of Diaries Misclassified by Novel Response Definition | ITTI Population | 0.20131 | diaries | ||
| Correlation Coefficient for Sustained Response and Return to Usual Health | ITTI Population | 0.51 | correlation coefficient | ||
| Time to Return to Usual Health, Placebo-Treated Subjects by Baseline Antibody Status | Placebo-Treated Subjects With Detectable Antibodies at Baseline | 224.1 | Inter-Quartile Range 128 to 359 | hours | |
| Time to Return to Usual Health, Placebo-Treated Subjects by Baseline Antibody Status | Placebo-Treated Subjects Without Detectable Antibodies at Baseline | 261.5 | Inter-Quartile Range 162 to 504 | hours | |
| Time to Sustained Clinical Recovery | Nitazoxanide | 172.2 | Inter-Quartile Range 81 to 346 | hours | |
| Time to Sustained Clinical Recovery | Placebo | 176.4 | Inter-Quartile Range 82 to 347 | hours | |
| Time to Sustained Clinical Recovery by Antibody Status, Placebo-Treated Subjects | Placebo-Treated Subjects With Detectable Antibodies at Baseline | 141.0 | Inter-Quartile Range 80 to 281 | hours | |
| Time to Sustained Clinical Recovery by Antibody Status, Placebo-Treated Subjects | Placebo-Treated Subjects Without Detectable Antibodies at Baseline | 247.0 | Inter-Quartile Range 104 to 457 | hours | |
| Time to Sustained Clinical Recovery, Subjects Without Detectable Antibodies at Baseline | Nitazoxanide | 175.4 | Inter-Quartile Range 84 to 321 | hours | |
| Time to Sustained Clinical Recovery, Subjects Without Detectable Antibodies at Baseline | Placebo | 247.0 | Inter-Quartile Range 104 to 457 | hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03336619/results